Literature DB >> 18029831

Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.

Lionel L Bañez1, Robert J Hamilton, Alan W Partin, Robin T Vollmer, Leon Sun, Carmen Rodriguez, Yiting Wang, Martha K Terris, William J Aronson, Joseph C Presti, Christopher J Kane, Christopher L Amling, Judd W Moul, Stephen J Freedland.   

Abstract

CONTEXT: Recent studies have suggested that obese men have lower serum prostate-specific antigen (PSA) concentrations than nonobese men. Because men with higher body mass index (BMI) have greater circulating plasma volumes, lower PSA concentrations among obese men may be due to hemodilution.
OBJECTIVE: To determine the association between hemodilution and PSA concentration in obese men with prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of men who underwent radical prostatectomy for prostate adenocarcinoma from 1988 to 2006, using data from the databases of the Shared Equal Access Regional Cancer Hospital (n = 1373), Duke Prostate Center (n = 1974), and Johns Hopkins Hospital (n = 10 287). Multivariate linear regression models adjusting for clinicopathological characteristics were used to analyze the main outcome measures. MAIN OUTCOME MEASURES: Associations between BMI and mean adjusted PSA concentrations, mean plasma volume, and mean adjusted PSA mass (total circulating PSA protein, calculated as PSA concentration multiplied by plasma volume), assessed by determining P values for trend.
RESULTS: After controlling for clinicopathological characteristics, higher BMI was significantly associated with higher plasma volume (P < .001 for trend) and lower PSA concentrations (P < or = .02 for trend) in all cohorts. In 2 of the 3 cohorts, PSA mass did not change significantly with increasing BMI. In the third cohort, higher BMI was associated with increased PSA mass (P < .001 for trend), but only between BMI category less than 25 and the other categories.
CONCLUSIONS: In men undergoing radical prostatectomy, higher BMI was associated with higher plasma volume; hemodilution may therefore be responsible for the lower serum PSA concentrations among obese men with prostate cancer. Prospective studies are needed to evaluate this association in screened populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029831     DOI: 10.1001/jama.298.19.2275

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  106 in total

Review 1.  Lifestyle and dietary factors in the prevention of lethal prostate cancer.

Authors:  Kathryn M Wilson; Edward L Giovannucci; Lorelei A Mucci
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

2.  A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia.

Authors:  Yasukazu Nakanishi; Hitoshi Masuda; Satoru Kawakami; Mizuaki Sakura; Yasuhisa Fujii; Kazutaka Saito; Fumitaka Koga; Masaya Ito; Junji Yonese; Iwao Fukui; Kazunori Kihara
Journal:  Asian J Androl       Date:  2012-07-09       Impact factor: 3.285

Review 3.  Energetics in colorectal and prostate cancer.

Authors:  Jeffrey A Meyerhardt; Jing Ma; Kerry S Courneya
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

4.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

5.  Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort.

Authors:  Lourdes Guerrios-Rivera; Lauren Howard; Jennifer Frank; Amanda De Hoedt; Devon Beverly; Delores J Grant; Cathrine Hoyo; Stephen J Freedland
Journal:  Urology       Date:  2017-04-10       Impact factor: 2.649

6.  Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels.

Authors:  Keisuke Goto; Hirotaka Nagamatsu; Jun Teishima; Yuki Kohada; Shinsuke Fujii; Yoshimasa Kurimura; Koji Mita; Masanobu Shigeta; Satoshi Maruyama; Yoji Inoue; Mitsuru Nakahara; Akio Matsubara
Journal:  Mol Clin Oncol       Date:  2017-04-10

7.  Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.

Authors:  Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal
Journal:  BJU Int       Date:  2014-10-20       Impact factor: 5.588

8.  The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy.

Authors:  Lionel L Bañez; Simone Albisinni; Stephen J Freedland; Andrea Tubaro; Cosimo De Nunzio
Journal:  World J Urol       Date:  2012-07-31       Impact factor: 4.226

9.  Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging.

Authors:  Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Luigi Ferrucci; Anna Kettermann; E Jeffrey Metter
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

10.  Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate.

Authors:  Andrew Rundle; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-23       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.